We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Rejuvenon has received word from the FDA that its investigational compound,
RC-1291, a small-molecule ghrelin mimetic, has been granted fast-track status.
The long-term effects of botulinum toxin Type A (Botox) in patients with severe
movement disorders confirm the safety of the toxin's use in controlled dosages,
according to a recent study at Baylor College of Medicine (BCM) in Houston.
Scientists have successfully grown human brain cells in the laboratory for
the first time and used them to repair the damaged brains of head-injury victims,
according to The Australian.
Ropinirole is safe and effective for the treatment of restless legs syndrome
(RLS), according to the results of a randomized, multinational trial published
in Movement Disorders.
Pro-Pharmaceuticals, a developer of novel carbohydrate compounds that enable
the targeted delivery of chemotherapy drugs to cancer cells, has completed the
enrollment of patients in its Phase I clinical trial to evaluate Davanat alone
and in combination with the chemotherapeutic drug 5-Fluorouracil in refractory
patients with solid tumors.
RegeneRx Biopharmaceuticals has announced a second Phase II clinical trial to
test its drug, Thymosin beta 4 (TB4), for the treatment of venous stasis ulcers.
Maxim Pharmaceuticals has announced that, based on ongoing correspondence with
the FDA as well as consultations with external advisers, an additional Phase
III clinical trial will be necessary to further evaluate Ceplene plus Interleukin-2
(IL-2) combination therapy for the treatment of acute myeloid leukemia (AML)
patients in complete remission before applying for regulatory approval in the
U.S.
deCODE genetics has submitted an investigational new drug application to the
FDA for DG041, a novel, first-in-class, orally administered small molecule for
the treatment of peripheral arterial occlusive disease (PAOD).
Bristol-Myers Squibb (BMS) and Medarex have announced that the global development
and commercialization collaboration agreement, previously announced by both
companies Nov. 8, 2004, has become effective.
Abgenix will receive a milestone payment from Amgen triggered by Amgen's advancement
of an undisclosed antibody, created using Abgenix's proprietary XenoMouse
technology, into clinical trials.